---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: OptimUM-02"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: OptimUM-02. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 86 evidence topics quoted from 20 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence/optimum-02"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: OptimUM-02

<a id="heading-3.1.1"></a>

## 3.1.1 OptimUM-02

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Study purpose in the ClinicalTrials.gov record

> “This study is designed as a multi-stage Phase 2 study within a Phase 3 study to evaluate the safety, tolerability, pharmacokinetics, dose-exposure relationship, and anti-tumor activity of IDE196 in combination with crizotinib compared to the comparator arm of investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.1-2"></a>

#### Phase 2a, phase 2b, and phase 3 objectives in the EU trial record

> “Phase 2a: To determine the optimal dose of IDE196 + crizotinib combination in Phase 2a in order to establish the recommended dose for Phase 2b and Phase 3”
> “Phase 2b: To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to PFS per RECIST 1.1 as assessed by blinded independent central review (BICR)”
> “Phase 3:To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to OS”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.1-3"></a>

#### Secondary objectives in the EU trial record

> “Phase 3, Options 1 and 2: To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to objective response rate (ORR) per RECIST v1.1 as assessed by BICR”
> “Phase 3, Option 3: To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to PFS and ORR per RECIST v1.1 as assessed by BICR”
> “To evaluate the safety and tolerability of IDE196 in combination with crizotinib”
> “To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to PFS per RECIST v1.1 as assessed by investigator”
> “To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to objective response and DOR per RECIST v1.1 as assessed by investigator”
> “To compare IDE196 + crizotinib to investigator’s choice of treatment with respect to quality-of-life scores.”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.1-4"></a>

#### Aim of the primary analysis in the ASCO 2026 abstract

> “Here we present primary safety & efficacy results from the nested phase 2/3 OptimUM-02 trial of darova+crizo as first-line treatment for HLA-A2 negative-mUM.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.1-5"></a>

#### Aim of the subgroup analysis in the ESMO 2026 poster

> “Here, we present efficacy results from OptimUM-02 across subgroups defined by key baseline characteristics, including historically difficult to treat populations (e.g., high baseline LDH, extra-hepatic disease, or large lesions)”
> “Results were also compared with findings from the OptimUM-01 trial to assess consistency of response across studies”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Study status, dates, and number of sites in the ClinicalTrials.gov record

| Study characteristic | Quoted record |
| --- | --- |
| Overall status | “Active, not recruiting” |
| Study start (actual) | “2023-10-31” |
| Primary completion (estimated) | “2027-01-15” |
| Study completion (estimated) | “2028-01-15” |
| Sites | “This study has 68 locations” |
| Last update posted | “Last Update Posted 2026-02-17” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.2-2"></a>

#### Countries with listed sites in the ClinicalTrials.gov record

| Country | Example of a listed site location |
| --- | --- |
| United States | “Philadelphia, Pennsylvania, United States, 19107” |
| Australia | “Melbourne, Victoria, Australia, 3000” |
| Belgium | “Brussels, Belgium, 1200” |
| Canada | “Toronto, Ontario, Canada, M5G 2M9” |
| France | “Paris, France, 75005” |
| Germany | “Heidelberg, Baden-Wurttemberg, Germany, 69120” |
| Israel | “Jerusalem, Israel, 91120” |
| Italy | “Milan, Italy, 20133” |
| Netherlands | “Leiden, Netherlands, 2333 ZA” |
| Poland | “Warsaw, Poland, 02-781” |
| Spain | “Madrid, Spain, 28046” |
| Switzerland | “Zurich, Switzerland, 8058” |
| United Kingdom | “Glasgow, United Kingdom, G12 0YN” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.2-3"></a>

#### European Union dates in the EU trial record

| Field | Quoted record |
| --- | --- |
| Start date in the European Union | “2024-10-09” |
| Estimated recruitment start date | “2024-07-01” |
| Estimated global end date | “2027-12-31” |

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.2-4"></a>

#### Enrollment progress in December 2024

> “Over 185 patients enrolled in potential registration-enabling trial in 1L HLA-A2-Negative MUM, and the darovasertib and crizotinib combination has received U.S. Food and Drug Administration (FDA) Fast Track designation in MUM”

Source: [IDEAYA Biosciences press release, IDMC move-forward dose recommendation (2024)](https://media.ideayabio.com/2024-12-17-IDEAYA-Announces-IDMC-Recommendation-of-Move-Forward-Dose-in-Part-2a-of-Registration-Enabling-Trial-of-Darovasertib-and-Crizotinib-Combination-in-1L-HLA-A2-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.2-5"></a>

#### Enrollment progress and international sites as of February 2025

> “We have enrolled over 230 patients as of February 7, 2025, and have opened multiple clinical sites, including international sites, in our potential registration-enabling Phase 2/3 clinical trial, designated as IDE196-002.”

Source: [IDEAYA Biosciences Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025022183/idya-20241231.htm)

<a id="topic-3.1.1.2-6"></a>

#### Data cutoff of the primary analysis presented at ASCO 2026

> “Data presented at ASCO were as of a cutoff date of January 23, 2026 and included additional detail on baseline characteristics as well as safety, secondary endpoints and median PFS across patient subgroups.”
> “The data were provided in a late-breaking oral presentation by Dr. Marlana Orloff, M.D., Professor of Medical Oncology at Thomas Jefferson University Hospital and lead investigator on the trial.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

<a id="topic-3.1.1.2-7"></a>

#### Subgroup analysis presented at ESMO 2026

> “Presented at the 2026 ESMO Congress, October 23–27, 2026 Madrid, Spain.”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Multi-stage randomized open-label design in the ClinicalTrials.gov record

> “This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).”
> “The Phase 2a dose optimization stage will evaluate two doses of IDE196 in combination with crizotinib compared to the comparator arm. Participants will be randomized to the three treatment arms. At the point of optimal IDE196 + crizotinib dose selection, the other dose arm will be dropped with discontinuation of enrollment to that arm. Participants receiving the IDE196 dose (in combination with crizotinib) that is not selected, will be offered the choice to remain on the same dose or change to the chosen optimal dose.”
> “The optimal dose will be chosen to complete the Phase 2b portion. The Phase 2b part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms.”
> “The Phase 3 part of the study will continue to enroll the chosen combination dose of IDE196 + crizotinib compared with the comparator arm. Participants will be randomized to the two treatment arms to evaluate the primary endpoint of overall survival (OS).”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.3-2"></a>

#### Allocation, assignment model, and masking in the ClinicalTrials.gov record

| Design characteristic | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.3-3"></a>

#### Randomization ratios and stratification factors in the ASCO 2026 presentation

> “Phase 2/3, multi-center, multi-arm, multi-stage, open-label study”
> “Patients will be stratified by baseline LDH (≤ULN vs >ULN, but less than 2-fold the ULN vs ≥ 2-fold the ULN) and investigator’s choice of comparator treatment (ipilimumab + nivolumab vs single-agent therapy).”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Study stage | Randomization ratio shown in the study design figure |
| --- | --- |
| Phase 2a (darovasertib 300 mg BID plus crizotinib, darovasertib 200 mg BID plus crizotinib, investigator's choice) | “2:2:1” |
| Phase 2b and phase 3 (darovasertib 300 mg BID plus crizotinib, investigator's choice) | “2:1” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.3-4"></a>

#### Randomization of first-line HLA-A2-negative participants in the ASCO 2026 abstract

> “OptimUM-02 is an open-label study of HLA-A2 negative first-line mUM patients who were randomized 2:1 to receive darova 300 mg plus crizo 200 mg BID or investigator’s choice (IC) of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.3-5"></a>

#### Random assignment in the phase 2b and phase 3 portions as reported from the ASCO 2026 presentation

> “In the phase IIb and phase III portions, patients were randomly assigned 2:1 to receive darovasertib at 300 mg twice-daily plus crizotinib at 200 mg twice-daily or investigator’s choice of pembrolizumab, ipilimumab/nivolumab, or dacarbazine.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-3.1.1.3-6"></a>

#### Integrated study-in-study design after the FDA Type C meeting, April 2023

> “The protocol includes an integrated Phase 2/3 open-label study-in-study design in first-line MUM patients with an HLA-A*02:01 negative serotype.”
> “The treatment arm of the Phase 2 portion includes a nested study to confirm the move forward combination dose for the integrated Phase 2/3 clinical trial – including cohorts at the Phase 2 expansion doses of (i) darovasertib 300 mg BID + crizotinib 200 mg BID and (ii) darovasertib 200 mg BID + crizotinib 200 mg BID.”
> “Under the nested study design, patients enrolled in the cohort at the move forward dose will be included within the Phase 2/3 registrational clinical trial.”

Source: [IDEAYA Biosciences press release, FDA Type C meeting and interim phase 2 data (2023)](https://media.ideayabio.com/2023-04-23-IDEAYA-Announces-Positive-Interim-Phase-2-Data-for-Darovasertib-and-Crizotinib-Combination-and-Successful-FDA-Type-C-Meeting-on-Registrational-Trial-Design-for-Accelerated-Approval-in-First-Line-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.3-7"></a>

#### Completion of phase 2a dose optimization on an independent data monitoring committee recommendation, December 2024

> “Independent Data Monitoring Committee (IDMC) recommends move-forward dose in Part 2a of potential registration-enabling trial in 1L HLA-A2-Negative MUM, based on clinical efficacy and safety observed”
> “SAN FRANCISCO, Dec. 17, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the Independent Data Monitoring Committee (IDMC) recommendation of a move-forward dose and the completion of the Part 2a dose optimization consistent with the U.S. Food and Drug Administration's (FDA) Project Optimus guidelines for the potential registration-enabling Phase 2/3 trial evaluating the combination of darovasertib and crizotinib in the first-line (1L) setting in patients with HLA-A2-negative (HLA-A2(-)) metastatic uveal melanoma (MUM).”

Source: [IDEAYA Biosciences press release, IDMC move-forward dose recommendation (2024)](https://media.ideayabio.com/2024-12-17-IDEAYA-Announces-IDMC-Recommendation-of-Move-Forward-Dose-in-Part-2a-of-Registration-Enabling-Trial-of-Darovasertib-and-Crizotinib-Combination-in-1L-HLA-A2-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.3-8"></a>

#### Crossover from the control arm

No evidence found.

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

| Inclusion criterion | Quoted record |
| --- | --- |
| Diagnosis | “Histological or cytological confirmed Metastatic Uveal Melanoma” |
| HLA type required | “HLA-A*02:01 negative” |
| Prior therapy | “No prior systemic therapy in the metastatic or advanced setting regional or liver-directed therapy. Ablations or surgical resection of oligometastatic disease, and neoadjuvant or adjuvant therapy is allowed” |
| Measurable disease | “Measurable disease per RECIST 1.1” |
| Ability to take study therapy | “Able to be safely administered and absorb study therapy” |
| Performance status | “ECOG performance status 0 or 1” |
| Life expectancy | “Life expectancy of ≥3 months” |
| Organ function | “Adequate organ function” |
| Ages eligible | “18 Years and older (Adult,  Older Adult )” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.4-2"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Previous treatment with a PKC inhibitor (including prior treatment with IDE196), an inhibitor directly targeting MET, or an inhibitor directly targeting GNAQ/11”
> “AEs from prior anti-cancer therapy that have not resolved to Grade ≤1”
> “Symptomatic or untreated central nervous system (CNS) metastases, or CNS metastases that require corticosteroids”
> “High risk of syncope or falls”
> “Active adrenal insufficiency, active colitis, or active inflammatory bowel disease”
> “History of interstitial lung disease, active pneumonitis, or history of pneumonitis requiring steroids”
> “Active infection requiring systemic antibiotic therapy or active Hepatitis B/C”
> “Major surgery, radiotherapy, or use of hematopoietic colony-stimulating factors (CSF) within 2 weeks prior to start of study drug”
> “Females who are pregnant or breastfeeding”
> “History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies”
> “Contraindication for treatment with investigator's choice therapies as per applicable labelling”
> “History of stroke within the last 6 months of the first dose of study drug”
> “Impaired Cardiac function or clinically significant cardiac diseases, including angina pectoris or acute myocardial infarction <= 6 months prior to start of study treatment”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.4-3"></a>

#### Prior treatment requirements in the EU trial record

> “No prior systemic therapy in the metastatic or advanced setting including chemotherapy, immunotherapy, or targeted therapy”
> “No prior regional, liver-directed therapy including chemotherapy, radiotherapy, or embolization”
> “Prior ablations or surgical resection of oligometastatic disease are allowed”
> “Prior neoadjuvant or adjuvant therapy is allowed provided administered in the curative setting in participants with localized disease and a minimum of 4 weeks (28 days) has elapsed since the end of neoadjuvant/adjuvant treatment and the start of study treatment”
> “Participants who have received a combination of anti-programmed cell death ligand 1 (PD-L1) plus anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) as prior neoadjuvant/adjuvant treatment should not receive ipilimumab + nivolumab as investigator’s choice therapy”
> “Participants who have received an anti-PD-L1 agent as prior neoadjuvant/adjuvant treatment should not receive pembrolizumab as investigator’s choice therapy”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.4-4"></a>

#### Tissue, measurable disease, and first-line status in the EU trial record

> “Has a representative archival metastatic tumor specimen in paraffin blocks with an associated pathology report or a minimum of 16 formalin-fixed paraffin embedded (FFPE) slides is mandatory.”
> “The participants in this study are frontline MUM patients. Participants are eligible for this trial if they are initially diagnosed with MUM or after therapy for localized UM that has subsequently metastasized.”
> “Has measurable disease per RECIST v1.1, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥10 mm with computer tomography (CT) or magnetic resonance imaging (MRI) scan.”
> “Must be at least 18 years of age.”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.4-5"></a>

#### Laboratory thresholds for adequate organ function in the EU trial record

> “Absolute neutrophil count (ANC) ≥ 1500/mm3 without the use of hematopoietic growth factors”
> “Hemoglobin ≥ 9.0 g/dL (must be at least 2 weeks post-red blood cell transfusion)”
> “AST and ALT ≤ 3 × ULN in the absence of documented liver metastases; ≤ 5 × ULN in the presence of liver metastases”
> “Serum albumin ≥ 3.0 g/dL.”
> “Creatinine clearance ≥ 45 mL/min by Cockcroft-Gault equation (see Appendix 1, Section 14.1).”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.4-6"></a>

#### Syncope, cardiac, and concomitant medication exclusions in the EU trial record

> “History of syncope (except due to an acute medical condition [e.g., hemorrhage] within 6 months of the first dose of study treatment and is not likely to reoccur).”
> “Participants at high risk of falls should be considered ineligible.”
> “QTcF > 470 msec on baseline ECG (mean of baseline values).”
> “Has other clinically significant heart disease (e.g., uncontrolled arrhythmia or hypertension; history of labile hypertension or poor compliance with an antihypertensive regimen, symptomatic bradycardia)”
> “Has an allergy to mammalian meat products or gelatin.”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.4-7"></a>

#### Contraindication to comparator options and restricted use of dacarbazine in the EU trial record

> “Contraindication for treatment with investigator’s choice alternatives (dacarbazine, ipilimumab + nivolumab, and pembrolizumab) as per applicable labelling.”
> “Participants may have a contraindication to one or two of the choices if he/she is a candidate for dosing with at least one investigator’s choice and meets all other study eligibility criteria.”
> “Choice of dacarbazine should only be made in the setting where treatment with immunotherapy is deemed likely to result in irreversible serious (or life threatening) AEs (e.g., severe active autoimmune disease requiring potent immunosuppression) and must be discussed with the Sponsor Medical Monitor.”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Darovasertib and crizotinib doses, run-in, and comparator regimens in the ASCO 2026 presentation

| Arm or regimen | Dose shown in the study design figure |
| --- | --- |
| Phase 2a and phase 2b/3 selected-dose arm, darovasertib | “Darovasertib (300 mg BID)” |
| Phase 2a and phase 2b/3 combination arms, crizotinib | “Crizotinib (200 mg BID)” |
| Phase 2a lower-dose arm, darovasertib | “Darovasertib (200 mg BID)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

> “Treatment will commence with a 7-day run-in of darovasertib monotherapy (at dose corresponding to the treatment arm, and the run-in may be extended if clinically indicated) prior to starting crizotinib.”
> “Treatment will continue until disease progression, death (any cause), unacceptable toxicity or treatment discontinuation”
> “Dacarbazine, dacarbazine (1000 mg/m2 Q3W). Ipi+Nivo, ipilimumab (3 mg/kg) + nivolumab (1 mg/kg) for 4 cycles followed by nivolumab (1mg/kg).”
> “Pembro, pembrolizumab (200 mg Q3W).”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.5-2"></a>

#### Route and schedule of each intervention in the ClinicalTrials.gov record

| Intervention | Quoted route and schedule |
| --- | --- |
| IDE196 (darovasertib) and crizotinib | “Dosed orally, twice daily” |
| Pembrolizumab | “IV administration every 3 weeks” |
| Ipilimumab | “IV administration every 3 weeks for 4 Cycles” |
| Nivolumab | “IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance” |
| Dacarbazine | “IV administration every 3 Weeks” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

> “Participants will receive investigator's choice of Pembrolizumab, Ipilimumab + Nivolumab, or Dacarbazine.”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.5-3"></a>

#### Comparator stratum in the investigator's choice arm (ASCO 2026 presentation)

| Investigator's choice treatment at baseline (stratification), n (%) | Investigator's choice arm (N=103) |
| --- | --- |
| Ipilimumab + nivolumab | “79 ( 76.7)” |
| Pembrolizumab or dacarbazine | “24 ( 23.3)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

> “No patients received dacarbazine in the investigator’s choice arm”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.5-4"></a>

#### Comparator selection in the investigator's choice arm, ESMO 2026 poster

> “Ipilimumab-nivolumab was selected for 79 patients and pembrolizumab was selected for 24 patients for the control; none selected dacarbazine”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-3.1.1.5-5"></a>

#### Comparator received in the control arm as reported from the ASCO 2026 presentation

> “In the control arm, 76.7% of patients received ipilimumab/nivolumab, and the remainder received pembrolizumab. No patients ultimately received dacarbazine.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-3.1.1.5-6"></a>

#### Comparator composition in the topline release, which differs from the ASCO and ESMO counts

> “The ICT arm was composed of 76% (n=78) ipilimumab plus nivolumab (anti-CTLA-4/PD-1) and 24% (n=25) pembrolizumab (anti-PD-1).”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Progression-free Survival by Blinded Independent Central Review as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoints of each stage in the ClinicalTrials.gov record

| Primary outcome measure | Quoted description | Quoted time frame |
| --- | --- | --- |
| “Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following:” | “dose exposure response (safety and efficacy) relationship, plasma concentration profiles and pharmacokinetic (PK) parameters, treatment-emergent Adverse Events (TEAEs), laboratory abnormalities, electrocardiogram (ECG), and vital sign changes and study treatment discontinuation due to AEs.” | “Approximately 5 months” |
| “Phase 2 Progression-Free Survival (PFS)” | “by blinded independent central review (BICR) of IDE196 + Crizotinib compared to investigator's choice of treatment per RECIST v1.1” | “Approximately 2 years” |
| “Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment.” | “OS from randomization to date of death due to any cause” | “Approximately 4 years” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.6.1-2"></a>

##### Definitions of progression-free survival and overall survival in the EU trial record

> “PFS, defined as the time from randomization to the first documented date of disease progression or death due to any cause, whichever occurs first”
> “OS (time from randomization to date of death due to any cause”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.6.1-3"></a>

##### Primary and other endpoints in the ASCO 2026 abstract

> “The primary endpoint for efficacy for phase 2 was progression-free survival (PFS) by RECIST (BICR).”
> “Other endpoints included investigator assessed PFS (PFSinv), objective response rate (ORR), duration of response (DOR), disease control rate (DCR: CR+ PR + SD ≥ 12 weeks), and safety.”
> “Overall survival, the phase 3 primary endpoint, will be presented as the data matures.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.6.1-4"></a>

##### Median progression-free survival as the accelerated approval endpoint after the FDA Type C meeting, April 2023

> “Based on FDA meeting, initiating Phase 2/3 registrational trial in Q2 2023 in First-Line HLA-A2 negative MUM, with median PFS as primary endpoint for potential accelerated approval”
> “"These clinical data, considered with the FDA's guidance from our recent Type C meeting, provides IDEAYA with a registrational trial design in first-line HLA-A2 negative MUM patients which includes a path to potential accelerated approval based on median PFS as the primary endpoint," said Dr. Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.”
> “The clinical trial design employs a Phase 2 portion with median PFS as a primary endpoint for potential accelerated approval.”
> “Efficacy data from the Phase 3 could support potential approval using median OS as a primary endpoint.”

Source: [IDEAYA Biosciences press release, FDA Type C meeting and interim phase 2 data (2023)](https://media.ideayabio.com/2023-04-23-IDEAYA-Announces-Positive-Interim-Phase-2-Data-for-Darovasertib-and-Crizotinib-Combination-and-Successful-FDA-Type-C-Meeting-on-Registrational-Trial-Design-for-Accelerated-Approval-in-First-Line-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.6.1-5"></a>

##### Overall survival as the primary endpoint of the phase 3 confirmatory portion in the annual report for 2024

> “The protocol of the Phase 2/3 clinical trial design incorporates guidance and feedback following our Type C meeting with the FDA in March 2023.”
> “Patients enrolled in Phase 2 will continue on treatment within the same study and will be considered, together with additional enrolled patients, to evaluate OS as the primary endpoint of the Phase 3 confirmatory portion of the clinical trial to support a potential full approval.”

Source: [IDEAYA Biosciences Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025022183/idya-20241231.htm)

<a id="topic-3.1.1.6.1-6"></a>

##### Accelerated approval on a surrogate endpoint as described in the annual report for 2025

> “Accelerated approval is intended to allow for earlier approval of drugs that treat serious conditions and fill an unmet medical need based on a demonstration of effectiveness on a surrogate endpoint, with the requirement to conduct one or more additional studies to confirm the anticipated clinical benefit to obtain full traditional approval.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-3.1.1.6.1-7"></a>

##### Regulatory role of each primary endpoint in the full enrollment release, December 2025

> “The primary endpoints are median PFS and median OS, which will be used to support a potential accelerated approval and full approval in the United States, respectively.”

Source: [IDEAYA Biosciences press release, OptimUM-02 full enrollment (2025)](https://media.ideayabio.com/2025-12-11-IDEAYA-Biosciences-Completes-Targeted-Full-Enrollment-in-Randomized-Pivotal-Phase-2-3-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A2-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.6.1-8"></a>

##### Regulatory role of each primary endpoint in the topline and ASCO 2026 releases

> “The primary endpoint is median PFS as assessed by BICR, which will be used to support an initial NDA submission in the United States.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

> “The primary endpoint to support accelerated approval is median progression-free survival (PFS) as assessed by blinded independent central review (BICR).”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

<a id="topic-3.1.1.6.1-9"></a>

##### FDA guidance on progression-free survival as a regulatory endpoint

> “PFS is defined as the time from randomization until objective tumor progression or death, whichever occurs first.”
> “Compared with TTP, PFS is the preferred regulatory endpoint.”
> “PFS can reflect tumor growth and be assessed before the determination of a survival benefit. Its determination is not confounded by subsequent therapy. For a given sample size, the magnitude of effect on PFS can be larger than the effect on overall survival. Data are usually insufficient to allow a robust evaluation of the correlation between effects on overall survival and PFS.”
> “Treatment effect measured by PFS can be a surrogate endpoint to support accelerated approval, a surrogate endpoint to support traditional approval, or it can represent direct clinical benefit based on the specific disease, context of use, magnitude of the effect, the disease setting, location of metastatic sites, available therapy, the risk-benefit relationship, and the clinical consequences of delaying or preventing progression in key disease sites (e.g., delay of new lesions in the brain or spine) or delaying administration of more toxic therapies.”

Source: [FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.1.6.1-10"></a>

##### FDA guidance on blinded central review of tumor-based endpoints

> “When the primary study endpoint is based on tumor measurements (e.g., PFS or ORR), tumor assessments generally should be verified by central reviewers blinded to study treatments (see Appendix) to ascertain lack of assessment bias.”
> “An independent endpoint review committee (IRC) can minimize bias in radiographic interpretation of the radiological findings and independent adjudication of assessments.”

Source: [FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.1.6.1-11"></a>

##### FDA guidance on overall survival as an endpoint

> “Overall survival is defined as the time from randomization until death from any cause and is measured in the intent-to-treat population. Survival is considered the most reliable cancer endpoint, and when studies can be conducted to adequately assess survival, it is usually the preferred endpoint.”
> “Overall survival should be evaluated in randomized controlled studies.”

Source: [FDA guidance, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.1.6.1-12"></a>

##### FDA draft guidance on a single randomized trial supporting accelerated approval and verifying benefit

> “Alternatively, sponsors could design a single randomized controlled trial to support accelerated approval, that is also powered for the longer-term clinical endpoint with follow-up in the same trial to verify clinical benefit (i.e., “one-trial” approach).”

Source: [FDA draft guidance on accelerated approval of oncology therapeutics (2023)](https://www.fda.gov/media/166431/download)

> “Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy.”

Source: [FDA guidance page, accelerated approval of oncology therapeutics (2023)](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics)

<a id="topic-3.1.1.6.1-13"></a>

##### Historical progression-free and overall survival in metastatic uveal melanoma cited in the ESMO 2026 poster

> “Historically, mUM has been associated with a median progression free survival (mPFS) of 2.8 months and a median overall survival (mOS) of ~12 months”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-3.1.1.6.1-14"></a>

##### Disease control definition and imaging interval as reported from the ASCO 2026 presentation

> “Dr. Orloff noted that disease control was defined as complete response, partial response, or stable disease lasting at least 12 weeks, with imaging performed every 6 weeks.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-3.1.1.6.1-15"></a>

##### Secondary efficacy and safety endpoints in the ClinicalTrials.gov record

> “Treatment emergent adverse events will be summarized by all AEs, including by Grade ≥3, all treatment related AEs, all AEs leading to study drug modifications or discontinuations, all SAEs as measured by CTCAE v5.0.”
> “Phase 2b + 3: Progression-Free Survival (PFS) per Investigator Assessment of IDE196 + Crizotinib compared to investigator's choice of treatment .”
> “Objective Response Rate (ORR) per BICR and Investigator assessment of IDE196 + Crizotinib compared to investigator's choice of treatment”
> “Duration of Response (DOR) per BICR and Investigator assessment of IDE196 + Crizotinib compared to investigator's choice of treatment”
> “Disease Control Rate (DCR) per BICR and Investigator Assessment of IDE196 + Crizotinib compared to investigator's choice of treatment.”
> “Time to response as assessed by Investigator and BICR”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.6.1-16"></a>

##### Definitions of response endpoints in the EU trial record

> “ORR, defined as the proportion of participants with a complete response (CR) or a partial response (PR) as best objective response (BOR)”
> “Disease control rate (DCR), defined as CR or PR, or stable disease (SD) ≥ 12 weeks”
> “DOR, defined as the time from the first documented evidence of a CR or PR until disease progression or death due to the underlying disease, whichever occurs first”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-3.1.1.6.1-17"></a>

##### Patient-reported outcome endpoints in the ClinicalTrials.gov record and the EU trial record

> “Change from baseline over time and between treatment arms in Global health status and quality of life will be assessed using the EORTC QLQ-C30 questionnaire.”
> “The score range for the EORTC QLQ-C30 is from 0 to 100, with higher scores indicating better functioning and better global health status and health-related in EORTC QLQ-C30 scores”

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

> “Change from baseline over time and between treatment arms in European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EuroQoL (EQ)-5D- 5L scores”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned enrollment of 420 participants in the current ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Enrollment (estimated) | “420” |

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332)

<a id="topic-3.1.1.7.1-2"></a>

##### Planned enrollment of 420 participants from record version 39, November 2024

| Field | Quoted record |
| --- | --- |
| Record version viewed | “Viewing V39 (2024-11-05)” |
| Enrollment | “420 [Estimated]” |

Source: [ClinicalTrials.gov NCT05987332 version 39](https://clinicaltrials.gov/study/NCT05987332?tab=history&a=39)

<a id="topic-3.1.1.7.1-3"></a>

##### Planned enrollment of 380 participants in record version 1, August 2023, superseded in November 2024

| Field | Quoted record |
| --- | --- |
| Record version viewed | “Viewing V1 (2023-08-03)” |
| Enrollment | “380 [Estimated]” |

Source: [ClinicalTrials.gov NCT05987332 version 1](https://clinicaltrials.gov/study/NCT05987332?tab=history&a=1)

<a id="topic-3.1.1.7.1-4"></a>

##### Planned phase 2 and phase 3 sample sizes after the FDA Type C meeting, April 2023, superseded in December 2025

> “In the Phase 2 portion of the clinical trial, approximately 230 patients will be randomized on a 2:1 basis for treatment with the darovasertib and crizotinib combination in the treatment arm or investigators choice in the control arm, selected from a combination of ipilimumab (ipi) and nivolumab (nivo), PD1-targeted monotherapy or DTIC.”
> “The Phase 2 portion of the clinical trial contemplates an efficacy and safety data set of approximately 200 patients randomized 2:1 with the treatment arm at the move forward dose to support a potential accelerated approval based on median PFS by blinded independent central review (BICR) as a primary endpoint.”
> “Patients enrolled in Phase 2 at the selected dose would continue on treatment and be included in the Phase 3 study analysis, supplemented by enrollment of approximately 120 additional patients into the Phase 3 portion of the clinical trial with 2:1 randomization on the same basis as the Phase 2 portion.”

Source: [IDEAYA Biosciences press release, FDA Type C meeting and interim phase 2 data (2023)](https://media.ideayabio.com/2023-04-23-IDEAYA-Announces-Positive-Interim-Phase-2-Data-for-Darovasertib-and-Crizotinib-Combination-and-Successful-FDA-Type-C-Meeting-on-Registrational-Trial-Design-for-Accelerated-Approval-in-First-Line-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.7.1-5"></a>

##### Completed enrollment of 435 participants in the full enrollment release, December 2025

> “SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM).”

Source: [IDEAYA Biosciences press release, OptimUM-02 full enrollment (2025)](https://media.ideayabio.com/2025-12-11-IDEAYA-Biosciences-Completes-Targeted-Full-Enrollment-in-Randomized-Pivotal-Phase-2-3-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A2-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.7.1-6"></a>

##### Completed enrollment of 437 participants in the annual report for 2025

> “In December 2025, we completed full enrollment of 437 patients in OptimUM-02, and plan to submit overall survival (OS) data from these patients, when available, to support a full approval filing in this indication.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-3.1.1.7.1-7"></a>

##### Statistical design of the phase 2b primary analysis in the ASCO 2026 presentation

> “130 PFS events were required to detect a hazard ratio of 0.55 with 90% power”
> “Stratified log-rank test at a 1-sided α of 2.5%”
> “The median PFS in the control arm was assumed to be 3 months”
> “The target HR of 0.55 represents a 45% reduction in the risk of disease progression or death”
> “Translates to approximately 5.5 months median PFS in the darovasertib + crizotinib arm assuming exponential distributions”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.7.1-8"></a>

##### Participants analyzed in the ASCO 2026 release

> “OptimUM-02 is a global, registrational Phase 2/3 trial evaluating a total of 313 patients with 1L HLA*A2:01 negative mUM, randomized 2:1 to the darovasertib combination or an investigator's choice of therapy (ICT) arm reflective of real-world clinical practice that included ipilimumab plus nivolumab (anti-CTLA-4/PD-1) or pembrolizumab (anti-PD-1).”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

<a id="topic-3.1.1.7.1-9"></a>

##### Testing hierarchy and alpha allocation for secondary endpoints and overall survival

No evidence found.

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Intent-to-treat efficacy population of the phase 2b portion in the ASCO 2026 presentation

> “All patients in the ITT population setting (phase 2b portion of trial)”
> “Darovasertib 300 mg + crizotinib 200 mg (n=210)”
> “Investigator’s Choice (control, n=103)”
> “Analysis based on both BICR and Investigator assessments”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.7.2-2"></a>

##### Safety population of 338 and efficacy population of 313 in the ASCO 2026 abstract

> “Overall 338 patients received at least one dose of study treatment (safety population), 313 comprised the efficacy population.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.7.2-3"></a>

##### Stratified and unstratified subgroup models in the ESMO 2026 poster

> “Unstratified: Subgroup hazard ratios were estimated from a single Cox proportional hazards model including treatment, subgroup, and treatment-by-subgroup interaction terms, with a common baseline hazard across subgroup levels.”
> “Stratified: The treatment hazard ratio was estimated using a Cox proportional hazards model stratified by prespecified factors, allowing each stratum to have its own baseline hazard while estimating a common treatment effect across strata.”
> “Efficacy, including progression-free survival (PFS) and objective response rate (ORR), were evaluated by BICR across key subgroups”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Participants without a post-baseline response assessment, by arm (ASCO 2026 presentation)

| Best overall response category | Darovasertib plus crizotinib (N=210), n (%) | Investigator's choice (N=103), n (%) |
| --- | --- | --- |
| Not reported (no post-baseline assessment), by BICR and by investigator | “12 (5.7)” | “24 (23.3)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

> “Refers to the patients who did not have any post-baseline assessments. Investigator Choice Treatment: (24): withdrew consent before treatment (17), before 1st post-baseline scan (2); due to AE (1, G3 hypoxia), clinical progression (1) and death (2), scan not recoverable from outside facility (1).”
> “Darovasertib + crizotinib Treatment: (12); due to death (7), withdrew consent before 1st post-baseline scan (1); due to clinical progression (1), scans performed after clinical cutoff (1), scans not performed at EOT or during post-treatment period (2).”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.1-2"></a>

##### Median follow-up and median duration of treatment in the ASCO 2026 presentation

> “Median follow-up for the population was 7.4 months.”
> “Median duration of treatment for darovasertib and crizotinib was 6.31 months; for pembrolizumab, ipilimumab, and nivolumab, the median duration of treatment were 2.87, 2.56, and 2.79 months, respectively.”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.1-3"></a>

##### Discontinuation of study treatment for adverse events, ASCO 2026 abstract

> “AEs led to discontinuation & dose reduction of darova in 3.8% & 23.8% and crizo in 10.9% & 27.2% subjects. In the IC arm, 19.2% discontinued due to AEs.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Demographics, performance status, and LDH stratum (ASCO 2026 presentation)

| Characteristic | Darovasertib plus crizotinib (N=210) | Investigator's choice (N=103) |
| --- | --- | --- |
| Age, mean (range), years | “61.1 (22 - 85)” | “61.5 (29 - 85)” |
| Female, n (%) | “101 (48.1)” | “52 (50.5)” |
| Race, White, n (%) | “177 (84.3)” | “83 (80.6)” |
| Race, non-White, n (%) | “4 (1.9)” | “4 (3.9)” |
| Race, not reported, n (%) | “29 ( 13.8)” | “16 ( 15.5)” |
| ECOG 0, n (%) | “162 (77.1)” | “87 (84.5)” |
| ECOG 1, n (%) | “48 (22.9)” | “16 (15.5)” |
| Stratification LDH at baseline (IRT), ≤ ULN, n (%) | “120 (57.1)” | “62 (60.2)” |
| Stratification LDH at baseline (IRT), > ULN to < 2x ULN, n (%) | “65 (31.0)” | “29 (28.2)” |
| Stratification LDH at baseline (IRT), ≥ 2x ULN, n (%) | “25 (11.9)” | “12 (11.7)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.2-2"></a>

##### Baseline tumor characteristics and metastatic sites (ASCO 2026 presentation)

| Characteristic | Darovasertib plus crizotinib (N=210) | Investigator's choice (N=103) |
| --- | --- | --- |
| Time since first metastatic diagnosis, median (range), years | “0.18 (0.0 – 8.1)” | “0.19 (0.0 – 4.6)” |
| Size of largest metastatic lesion ≤ 3 cm, n (%) | “119 ( 56.7)” | “67 ( 65.0)” |
| Size of largest metastatic lesion 3.1 to 8.0 cm, n (%) | “73 ( 34.8)” | “31 ( 30.1)” |
| Size of largest metastatic lesion ≥ 8.1 cm, n (%) | “18 (  8.6)” | “5 (  4.9)” |
| Hepatic disease only, n (%) | “127 ( 60.5)” | “65 ( 63.1)” |
| Extrahepatic disease only, n (%) | “11 (  5.2)” | “7 (  6.8)” |
| Hepatic and extrahepatic disease, n (%) | “72 ( 34.3)” | “31 ( 30.1)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.2-3"></a>

##### Participants by age group and geographic region in the PFS subgroup figure (ASCO 2026 presentation)

| Subgroup | Participants, darovasertib plus crizotinib and control |
| --- | --- |
| Age under 65 years | “118, 64” |
| Age 65 years or older | “92, 39” |
| Geographic region, USA | “74, 36” |
| Geographic region, non-USA | “136, 67” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.2-4"></a>

##### Comparator stratum and prior oligometastatic surgery (ESMO 2026 poster)

| Characteristic | Darovasertib 300 mg plus crizotinib 200 mg (N=210) | Investigator's choice (N=103) |
| --- | --- | --- |
| Control at baseline, ipilimumab + nivolumab, n (%) | “158 (75.2)” | “79 ( 76.7)” |
| Control at baseline, pembrolizumab or dacarbazine, n (%) | “52 (24.8)” | “24 ( 23.3)” |
| Prior oligometastatic-directed surgery, n (%) | “5 (2.4)” | “6 (5.8)” |

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

> “Baseline characteristics were generally similar across both arms”
> “Key relevant prognostic factors included ECOG performance status, site of metastasis, tumor burden, and baseline LDH levels”
> “There were more ECOG 1 and bulky liver lesions in the darova+criz group”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-3.1.1.8.2-5"></a>

##### Balance of baseline characteristics as reported from the ASCO 2026 presentation

> “Baseline characteristics were generally balanced between the two arms, although Dr. Orloff noted that numerically more patients in the darovasertib/crizotinib arm had an ECOG PS of 1 and larger tumors. Baseline LDH and metastatic patterns were well balanced; most patients had liver involvement.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Progression-free survival, 313 participants of the phase 2b/3 portion, data cutoff January 23, 2026

> “Topline results were from a total of 313 patients enrolled in the Phase 2b/3 portion of the trial as of the cut-off date of January 23, 2026. The PFS analysis was based on a total of 159 events.”
> “Patients treated with the darovasertib combination reduced their risk of disease progression as assessed by BICR by 58% (Hazard Ratio of 0.42; 95% CI: 0.30, 0.59; p-value: <0.0001) and achieved a statistically significant improvement in median PFS of 6.9 months versus 3.1 months in the ICT arm.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

> “The median PFS by BICR was 6.9 months for darova+crizo (5.6, 8.3) and 3.1 months for IC (1.8, 4.2); HR: 0.42, p<.0001. Median PFSinv was 6.7 months (5.6, 8.2) and 2.7 months (1.7, 4.1) resp; HR 0.36, p< 0.0001.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

| Outcome | By blinded independent central review | By investigator assessment |
| --- | --- | --- |
| Median PFS, darovasertib plus crizotinib, months (95% CI) | “Darova + Criz: 6.9 (5.6, 8.3)” | “Darova + Criz: 6.7 (5.6, 8.2)” |
| Median PFS, control, months (95% CI) | “Control: 3.1 (1.8, 4.2)” | “Control: 2.7 (1.7, 4.1)” |
| Hazard ratio (95% CI) | “HR = 0.42 (0.30, 0.59)” | “HR = 0.36 (0.26, 0.50)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

> “58% by BICR (HR: 0.42); 64% by investigator assessment (HR: 0.36), p < 0.0001”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.3-2"></a>

##### Objective response, best overall response, duration of response, and disease control, 210 and 103 participants by arm

> “Patients treated with the darovasertib combination had an ORR of 37.1% (78/210) and 39.5% (83/210) as assessed by BICR and investigator, respectively, compared to 5.8% (6/103) and 1.9% (2/103) in the ICT arm (p-value: <0.0001).”
> “The darovasertib combination led to a disease control rate of 73.3% (154/210) and 74.3% (156/210) by BICR and investigator assessment, respectively, compared to 31.1% (32/103) and 27.2% (28/103) in the ICT control arm.”
> “The median duration of response was 6.8 months (95% CI: 5.5, 11.3) by BICR and 6.8 months (95% CI: 4.8, 9.7) by investigator assessment based on a median follow-up time of 7.4 months as of the cutoff date.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

| Outcome | BICR, darovasertib plus crizotinib (N=210) | BICR, investigator's choice (N=103) | Investigator, darovasertib plus crizotinib (N=210) | Investigator, investigator's choice (N=103) |
| --- | --- | --- | --- | --- |
| Complete or partial response, n (%) | “78 (37.1)” | “6 (5.8)” | “83 (39.5)” | “2 (1.9)” |
| Objective response rate, 95% CI | “30.6, 44.1” | “2.2, 12.3” | “32.9, 46.5” | “0.2, 6.8” |
| Objective response, odds ratio (95% CI) | “10.8 (4.4, 26.4)” | Reference | “34.6 (8.1, 146.9)” | Reference |
| Median duration of response, months (95% CI) | “6.8 (5.5, 11.3)” | “NE” | “6.8 (4.8, 9.7)” | “NE” |
| Complete response, partial response, or stable disease for at least 12 weeks, n (%) | “154 (73.3)” | “32 (31.1)” | “156 (74.3)” | “28 (27.2)” |
| Disease control rate, 95% CI | “66.8, 79.2” | “22.3, 40.9” | “67.8, 80.1” | “18.9, 36.8” |
| Disease control, odds ratio (95% CI) | “7.7 (4.3, 13.5)” | Reference | “9.5 (5.3, 17.0)” | Reference |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Best overall response, n (%) | BICR, darovasertib plus crizotinib (N=210) | BICR, investigator's choice (N=103) | Investigator, darovasertib plus crizotinib (N=210) | Investigator, investigator's choice (N=103) |
| --- | --- | --- | --- | --- |
| Complete response | “5 (2.4)” | “0” | “0” | “0” |
| Partial response | “73 (34.8)” | “6 (5.8)” | “83 (39.5)” | “2 (1.9)” |
| Stable disease | “107 (51.0)” | “43 (41.7)” | “99 (47.1)” | “39 (37.9)” |
| Progressive disease | “13 (6.2)” | “29 (28.2)” | “15 (7.1)” | “34 (33.0)” |
| Non-evaluable by RECIST | “0” | “1 (1.0)” | “1 (0.5)” | “4 (3.9)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.3-3"></a>

##### Response, disease control, and duration of response, ASCO 2026 abstract

> “BICR ORR {37.1% [CR 2.4%; PR 34.8%] vs. 5.8% [CR 0%, PR 5.8%], DCR (73.3% vs 31.1%), DOR (median 6.8 months vs. Non-Evaluable) as well as ORRinv [39.5% vs. 1.9%], DCRinv [74.3% vs. 27.2%] and DORinv (6.8 months vs. NE) all favored darova+crizo (p-value < 0.0001).”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.8.3-4"></a>

##### Tumor shrinkage on waterfall plots and subgroup consistency as reported from the ASCO 2026 presentation

> “Dr. Orloff also noted that the waterfall plots showed tumor reduction in nearly 90% of patients in the darovasertib/crizotinib arm compared with about 35% in the control arm.”
> “The progression-free survival benefit was observed across the analyzed subgroups, including baseline LDH, investigator’s choice treatment category, age, sex, ECOG performance status, geographic region, largest target lesion size, and metastatic site.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-3.1.1.8.3-5"></a>

##### Objective response and median progression-free survival by BICR in subgroups, efficacy population of 313 participants (ESMO 2026 poster, stratified analysis)

| Subgroup (n, darovasertib plus crizotinib and control) | ORR by BICR, darovasertib plus crizotinib (%) | ORR by BICR, control (%) | Median PFS by BICR, darovasertib plus crizotinib (months) | Median PFS by BICR, control (months) |
| --- | --- | --- | --- | --- |
| LDH normal (n=120, 62) | “46.7” | “8.1” | “8.4” | “4.2” |
| LDH above ULN and below 2x ULN (n=65, 29) | “27.7” | “3.4” | “5.7” | “1.8” |
| LDH 2x ULN or higher (n=25, 12) | “16.0” | “0” | “3.1” | “1.7” |
| Hepatic metastases (n=127, 65) | “45.7” | “3.1” | “8.3” | “2.9” |
| Extrahepatic metastases only (n=11, 7) | “27.3” | “0” | “6.7” | “8.3” |
| Hepatic and extrahepatic metastases (n=72, 31) | “23.6” | “12.9” | “4.9” | “2.8” |
| ECOG PS 0 (n=162, 87) | “38.3” | “5.8” | “6.8” | “3.1” |
| ECOG PS 1 (n=48, 16) | “33.3” | “6.3” | “6.9” | “3.1” |
| Largest lesion below 3 cm (n=119, 67) | “42.9” | “6.0” | “8.3” | “4.0” |
| Largest lesion 3 to 8 cm (n=73, 31) | “34.3” | “6.5” | “5.6” | “1.6” |
| Largest lesion 8 cm or larger (n=18, 5) | “11.1” | “0” | “4.2” | “1.7” |
| Control stratum ipilimumab plus nivolumab (n=158, 79) | “37.3” | “5.1” | “6.9” | “3.1” |
| Control stratum pembrolizumab or dacarbazine (n=52, 24) | “36.5” | “8.3” | “5.8” | “2.8” |

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

> “Overall, 313 patients (darova+criz: 210; control:103) were enrolled and included in the analyses (Table 1)”
> “The median PFS by BICR was 6.9 months for darova+criz (5.6, 8.3) and 3.1 months for IC (1.8, 4.2); HR: 0.42, p<0.0001 (Table 2)”
> “Results were generally consistent for stratified and unstratified analyses”
> “PFS results were generally consistent across key subgroups, with most favoring darova+criz over control (Figure 2)”
> “Tumor response, as assessed by ORR, generally favored darova+criz across subgroups (Figure 3)”
> “BICR results for PFS and ORR were generally consistent regardless of baseline LDH, location of metastases, ECOG PS, lesion size, or investigator’s choice of therapy”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-3.1.1.8.3-6"></a>

##### Subgroup findings in the ASCO 2026 and ESMO 2026 releases

> “Treatment with the darovasertib combination demonstrated a consistent and meaningful improvement in median PFS relative to the ICT arm across a broad range of patient subgroups, including age and gender, type of immune therapy used in ICT, LDH stratification, ECOG status and site of metastasis.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

> “The ESMO data builds on these results, showing consistent improvements in ORR and PFS compared to ICT across multiple clinically relevant subgroups, including baseline lactate dehydrogenase (LDH) levels, ECOG performance status, largest target lesion size and choice of ICT used in the control arm.”
> “As expected, patients with higher tumor burden (lesion size ≥ 8 cm, LDH ≥ 2X ULN) had a worse prognosis, however outcomes were still better with the darovasertib combination compared to ICT.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

<a id="topic-3.1.1.8.3-7"></a>

##### Overall survival status at the primary analysis

> “OS data is not yet mature; however, an early trend toward improved OS was observed with the darovasertib combination arm versus ICT. OS data will be presented at a future date”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

> “Preliminary OS is also trending favorably.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

> “As noted in the topline results, data on overall survival (OS) was still immature as of the cutoff date, however, there was an early trend in OS improvement in the darovasertib combination arm relative to the ICT arm.”
> “IDEAYA will provide the next OS update as part of the pre-specified interim analysis.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

<a id="topic-3.1.1.8.3-8"></a>

##### Secondary endpoint wording in the quarterly report for the first quarter of 2026, which differs from the releases and the presentation

> “In April 2026, we reported positive topline data from OptimUM-02, which demonstrated a statistically significant improvement in the primary endpoint of progression free survival, as well as a statistically significant improvement in the secondary endpoint of overall survival rate as assessed by blinded independent central review.”

Source: [IDEAYA Biosciences Form 10-Q, first quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526206357/idya-20260331.htm)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

##### Quality-of-life data not presented at the ASCO 2026 primary analysis

> “He noted that quality-of-life data were not presented, which he considered important given the chronic administration of two oral targeted agents.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Treatment-related adverse events, phase 2a and 2b safety population of 239 and 100 participants (ASCO 2026 presentation)

> “Safety was evaluated in all patients (phase 2a and 2b) who received at least one dose of darovasertib 300 mg + crizotinib 200 mg or control”
> “Darovasertib 300mg + crizotinib 200 mg (N=239)”
> “Investigator’s Choice (control, N=100)”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Outcome | Darovasertib plus crizotinib (N=239) | Investigator's choice (N=100) |
| --- | --- | --- |
| Any TRAE, n (%) | “235 (98.3)” | “89 (89.0)” |
| Grade 3 or 4 TRAE, n (%) | “97 (40.6)” | “37 (37.0)” |
| Grade 5 TRAE, n (%) | “1 (0.4)” | “1 (1.0)” |
| Treatment-related serious adverse event, n (%) | “22 (9.2)” | “25 (25.0)” |
| TRAE leading to withdrawal, row not naming a drug, n (%) | “2 (0.8)” | “5 (5.0)” |
| TRAE leading to darovasertib withdrawal, n (%) | “6 (2.5)” | Not applicable |
| TRAE leading to crizotinib withdrawal, n (%) | “24 (10.0)” | Not applicable |
| TRAE leading to investigator's choice withdrawal, n (%) | Not applicable | “19 (19.0)” |
| TRAE leading to darovasertib dose reduction, n (%) | “56 (23.4)” | Not applicable |
| TRAE leading to crizotinib dose reduction, n (%) | “63 (26.4)” | Not applicable |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

> “Grade 5 SAEs: Hepatic failure in the darovasertib + crizotinib arm in a subject with extensive bulky liver metastases in both lobes considered unrelated by Sponsor; gastrointestinal hemorrhage in ICT arm”

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Most common TRAE of any grade (20% or more), darovasertib plus crizotinib arm | Darovasertib plus crizotinib (N=239), n (%) |
| --- | --- |
| Any TRAE | “235 ( 98.3)” |
| Diarrhea | “203 ( 84.9)” |
| Nausea | “179 ( 74.9)” |
| Peripheral edema | “160 ( 66.9)” |
| Vomiting | “119 ( 49.8)” |
| Dermatitis acneiform | “100 ( 41.8)” |
| Fatigue | “94 ( 39.3)” |
| Hypotension | “79 ( 33.1)” |
| Hypoalbuminemia, dysgeusia, and dizziness, each | “61 ( 25.5)” |
| Decreased appetite | “57 ( 23.8)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Most common TRAE of any grade (20% or more), investigator's choice arm | Investigator's choice (N=100), n (%) |
| --- | --- |
| Any TRAE | “88 ( 88.0)” |
| Diarrhea | “29 ( 29.0)” |
| Alanine aminotransferase increased, aspartate aminotransferase increased, fatigue, and nausea, each | “25 ( 25.0)” |
| Pruritus | “24 ( 24.0)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Grade 3 or 4 TRAE (2% or more), darovasertib plus crizotinib arm | Darovasertib plus crizotinib (N=239), n (%) |
| --- | --- |
| Any grade 3 or 4 adverse event | “97 ( 40.6)” |
| Diarrhea | “24 ( 10.0)” |
| Syncope | “17 (  7.1)” |
| Hypotension | “9 (  3.8)” |
| Nausea and peripheral edema, each | “7 (  2.9)” |
| Anemia | “6 (  2.5)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

| Grade 3 or 4 TRAE (2% or more), investigator's choice arm | Investigator's choice (N=100), n (%) |
| --- | --- |
| Any grade 3 or 4 adverse event | “37 ( 37.0)” |
| Alanine aminotransferase increased and aspartate aminotransferase increased, each | “7 (  7.0)” |
| Diarrhea | “6 (  6.0)” |
| Hepatitis | “5 (  5.0)” |
| Colitis | “4 (  4.0)” |
| Lipase increased, autoimmune hepatitis, and amylase increased, each | “3 (  3.0)” |
| Tubulointerstitial nephritis, hypophysitis, and hyperthyroidism, each | “2 (  2.0)” |

Source: [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf)

<a id="topic-3.1.1.8.5-2"></a>

##### Treatment-emergent adverse events of any cause, ASCO 2026 abstract

> “The most common treatment emergent adverse events (AEs) for darova+crizo were diarrhea (89.5%), nausea (78.2%), peripheral edema (70.7%), & vomiting (53.6%). In the IC arm, these were nausea (41.4%), diarrhea (36.3%), fatigue (33.3%), AST & ALT elevation (31.1%).”
> “The most common Grade 3 or 4 AEs for darova + crizo were diarrhea (10.9%) & syncope (7.9%) and for IC, AST & ALT increase (8.1%), diarrhea (6.1%) & hepatitis (5.1%).”
> “One treatment related fatal AE occurred in each arm.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.8.5-3"></a>

##### Treatment-related serious adverse events of 25.3% in the control arm, ASCO 2026 abstract

> “Treatment related serious AEs occurred in 9.2% and 25.3% on darova + crizo and IC respectively.”

Source: [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503)

<a id="topic-3.1.1.8.5-4"></a>

##### Treatment-related serious adverse events of 25.0% in the control arm and grade 3 or 4 events, ASCO 2026 release

> “Grade 3/4 treatment-related adverse events (TRAEs) occurred in 40.6% (97/239) of patients in the darovasertib combination arm compared to 37.0% (37/100) of patients in the ICT control arm.”
> “Treatment-related serious adverse events (TR-SAE) were 9.2% (22/239) and 25.0% (25/100) in the darovasertib combination and ICT arms, respectively.”
> “Median relative dose intensities of darovasertib and crizotinib were 91.0% and 77.1%, respectively, compared to 100% for the ICT arm.”

Source: [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO)

<a id="topic-3.1.1.8.5-5"></a>

##### Grade 3 or higher adverse events in the topline release

> “The most common Grade 3+ treatment emergent adverse events included diarrhea, syncope, and hypotension. The treatment-related serious adverse events rate in the darovasertib combination was in the single-digit percent range.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-3.1.1.8.5-6"></a>

##### Management of hypotension and syncope as reported from the ASCO 2026 presentation

> “Dr. Orloff discussed hypotension and syncope as distinctive toxicities associated with protein kinase C inhibition, noting that they were managed with hydration, holding blood pressure medications when appropriate, and a 7-day darovasertib run-in before crizotinib was added.”
> “In the investigator’s choice arm, the toxicity profile largely reflected checkpoint inhibitor therapy, with events including diarrhea, liver enzyme elevations, hepatitis, colitis, and endocrinopathies.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

OptimUM-02 is open label, with no masking. The primary analysis was reported at a median follow-up of 7.4 months; OS, the phase 3 primary endpoint, was not mature, and no OS estimate has been reported. The efficacy population of 313 participants is the intent-to-treat population of the phase 2b portion, which the topline release describes as enrolled in the phase 2b/3 portion; the safety analyses use different denominators, 338 participants in the ASCO 2026 abstract and 239 and 100 participants from phases 2a and 2b in the presentation. Reported enrollment is 435 participants in the full enrollment release and 437 in the annual report for 2025.

The comparator was investigator's choice: 79 participants (76.7%) received ipilimumab plus nivolumab, 24 (23.3%) pembrolizumab, and none dacarbazine (the topline release gives 78 and 25), and the EU trial record restricts dacarbazine to settings where immunotherapy is deemed likely to cause irreversible serious adverse events. No post-baseline response assessment was available for 24 participants (23.3%) in the control arm and 12 (5.7%) in the combination arm; 17 control participants withdrew consent before treatment. More participants in the combination arm had ECOG performance status 1 (22.9% vs 15.5%) and a largest metastatic lesion of 8.1 cm or more (8.6% vs 4.9%). Subgroups with LDH 2 times the ULN or higher, target lesion 8 cm or larger, or extrahepatic-only metastases had small numbers of participants and 95% confidence intervals that included the null value. Quality of life by the EORTC QLQ-C30 was a stated endpoint, and quality-of-life data were not presented at ASCO 2026. TRAEs led to dose reduction of darovasertib in 23.4% and of crizotinib in 26.4% of participants.

The sources conflict on several figures: the quarterly report for the first quarter of 2026 describes a statistically significant improvement in OS rate, while the presentation and releases describe OS as immature; any-grade TRAEs in the control arm are 89 (89.0%) in the summary table and 88 (88.0%) in the table of common events; treatment-related serious adverse events in the control arm are 25.0% in the presentation and release and 25.3% in the abstract; and one treatment-related fatal adverse event is reported in each arm while the grade 5 hepatic failure in the combination arm is described as considered unrelated by the sponsor.

Source: [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332); [Orloff et al. (2026a)](https://filecache.investorroom.com/mr5ir_ideayabio/616/OptimUM-02%20ASCO%20-%2026MAY2026.pdf); [Orloff et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA9503); [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma); [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO); [IDEAYA Biosciences press release, OptimUM-02 full enrollment (2025)](https://media.ideayabio.com/2025-12-11-IDEAYA-Biosciences-Completes-Targeted-Full-Enrollment-in-Randomized-Pivotal-Phase-2-3-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A2-Negative-Metastatic-Uveal-Melanoma); [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm); [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf); [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01); [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/); [IDEAYA Biosciences Form 10-Q, first quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526206357/idya-20260331.htm)

<a id="topic-3.1.1.9-2"></a>

#### Small subgroups with wide confidence intervals, ESMO 2026 poster

> “For select subgroup categories (i.e., LDH ≥2 × ULN, target lesion ≥8 cm, and extrahepatic-only metastases), the small number of participants resulted in wide 95% confidence intervals that included the null value, limiting the interpretation of treatment effect estimates in these categories”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-3.1.1.9-3"></a>

#### Discussant comments on immature overall survival, baseline imbalance, dose reductions, and open questions

> “He also pointed out that the progression-free survival benefit was seen despite slight baseline imbalances favoring the control arm.”
> “On safety, Dr. Lutzky said grade 3 and 4 toxicity rates were comparable to those seen with current therapies and that discontinuation rates remained relatively low, although about one-quarter of patients required dose reductions.”
> “He noted that several questions remain, including whether progression-free survival will translate into overall survival, how available treatments should be sequenced, whether targeted therapy can be safely combined with liver-directed approaches or immunotherapy, and whether these benefits can be moved into the adjuvant setting.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
